Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilars: FDA, EMA Developing Common Data Package Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

Guidance is “emerging” that will allow sponsors to use data from products not licensed in their respective regions in applications.

Advertisement

Related Content

Biosimilar Draft Guidance Outlines Three-Arm Bridging Studies For Non-U.S. Products
Biosimilar Draft Guidance Outlines Three-Arm Bridging Studies For Non-U.S. Products
FDA Oversight By House To Focus On User Fees, Compounding Law
Biosimilars in 2014: An Interview With FDA New Drugs Head John Jenkins
Naming Rights: Biosimilar Influence Efforts Continue Before Products Take The Field
Biosimilars: Does Low BsUFA Fee Revenue Suggest Sponsor Interest Has Stalled?
EMA Prepares For Biosimilar Reference Data From Non-EU Sources; U.S. Input Vital
Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain
FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics
FDA, EMA Seek Biosimilar Pathway Convergence

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077124

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel